Optometrists in Australia and New Zealand are invited to attend a free webinar on geographic atrophy.
‘The New Paradigm: Geographic Atrophy Treatment in Australia’ will be presented by Professor Robyn Guymer AM with Associate Professor Hemal Mehta, Dr Jennifer Arnold and Dr Amy Cohn.
The presenters will discuss existing and pipeline treatments for GA, and their mechanism of action. Additionally, they will explore characteristics of GA that you can see on imaging and what they tell us about risk and the risk of disease progression; patient selection for treatment, communication strategies for clinicians consulting GA patients, including setting expectations and strategies for co-management. An interactive Q and A will conclude the presentation.
The New Paradigm: Geographic Atrophy Treatment in Australia’ will be presented by Professor Robyn Guymer AM with Associate Professor Hemal Mehta, Dr Jennifer Arnold and Dr Amy Cohn
Accredited Education
‘The New Paradigm: Geographic Atrophy Treatment in Australia’ has been accredited by Optometry Australia for: 1.25Ti Institute of Excellence Quality Assured CPD hours, and 1G for Optometrists and Dispensing Opticians Board (ODOB) in New Zealand.
On completion of this webinar, participants will:
- Understand the current status of treatment availability for GA in Australia and the mechanism of action,
- Be aware of imaging available to diagnose GA and the characteristics to look for, including biomarkers,
- Understand criteria for patient selection for treatment,
- Be aware and able to manage patient expectations for treatment, and
- Understand the optometrist’s role in co-management of GA patients.
Register to Attend
Register to attend this important webinar on geographic atrophy.
Date: Tuesday 29 April 2025
Time: 6:30pm – 7:45pm AEST
About the Speakers
Professor Robyn H. Guymer AM MBBS FRANZCO PhD is an ophthalmologist with medical retinal subspeciality training. She is Professor of Ophthalmology at the University of Melbourne and Deputy Director of the Centre for Eye Research Australia. Prof Guymer sits on advisory boards of Apellis, Genentech, Roche, Novartis, and Bayer.
A/Prof Hemal Mehta MBBS MD(Cantab.) FRCOphth FRANZCO is an experienced macula disease specialist and cataract surgeon consulting in Sydney and the Central Coast. He is on the Therapeutics Committee of RANZCO and the editorial board of Journal ‘Eye’. The clinical research during his previous fellowships at Sydney Eye Hospital and Moorfields Eye Hospital contributed to his higher research degree from Cambridge University. He is Co-director of Clinical Trials Research at Strathfield Retina Clinic and has served as principal or sub-investigator in over 50 clinical trials. A/Prof Mehta has contributed to peer-reviewed publications and national guidelines on management of cataract in patients with macular disease.
Dr Amy Cohn FRANZCO MBBS (Hons) MMed is a Senior Research Fellow in Centre for Eye Research Australia’s macular research team and a Visiting Medical Officer at the Royal Victorian Eye and Ear Hospital. She consults privately at Armadale Eye Clinic, Armadale; Victorian Eye Surgeons, Footscray; Specialist Eye Group, Glen Waverley; and Melbourne Retina Associates, East Melbourne. Dr Cohn’s current areas of research include age-related macular degeneration, inherited eye conditions, and central cerous retinopathy. She has published widely and delivered several papers at international conferences. She has been involved in teaching new ophthalmology trainees at the Royal Victorian Eye and Ear Hospital.
Dr Jennifer Arnold MBBS FRANZCO is an ophthalmologist and ophthalmic surgeon, and a fellowship-trained medical retina specialist. She has a particular interest in age-related macular degeneration (AMD), as well as retino-vascular diseases such as diabetic eye disease.
Dr Arnold heads an active Clinical Trials and Research centre, conducting both natural history trials to better understand outcomes for people with retinal disease, as well as intervention treatment trials to test safety and efficacy of new therapies as well as better ways to use existing therapies. She has been Principal Investigator for >50 clinical trials in AMD and other retinal diseases over the past 21 years, and is on the board of Fight Retinal Blindness! an Australian based collaborative initiative
Sponsored by Astellas. This event is supported by an unrestricted educational grant and is created independently by mivision in collaboration with the speaker panel. All studies are selected by the panel and all views are those of the host and panel only.
